Seek Returns

BIO.B vs. HALO: Bio-Rad Laboratories vs. Halozyme Therapeutics Stock Comparison

How do Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO.B is classified in Life Sciences Tools & Services while HALO is classified in Biotechnology.

Company profile comparison for Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO)
Profile ItemBIO.BHALO
NameBio-Rad Laboratories, Inc. Class B Common StockHalozyme Therapeutics Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization10.49 billion USD11.43 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateSeptember 21, 1999March 16, 2004
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BIO.B
HALO
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO)
MetricBIO.BHALO
Total Return (1Y)27.69%40.85%
Total Return (3Y, Annualized)9.13%38.80%
Total Return (5Y, Annualized)-12.33%20.81%

Risk Profile

Drawdown History

BIO.B
HALO
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Halozyme Therapeutics (HALO) trades around 2.23M shares per day on average, while Bio-Rad Laboratories (BIO.B) sees only 11 — a volume gap that can matter for position sizing, exit liquidity, and order execution.

Risk profile metrics for Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO)
MetricBIO.BHALO
Volatility (1Y, Annualized)30.96%41.04%
Beta (5Y)1.000.92
Max Drawdown (5Y)-70.74%-49.06%
Avg. Volume (3M)112.23M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIO.B and HALO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO)
MetricBIO.BHALO
Sharpe Ratio (1Y)0.740.88
Sortino Ratio (1Y)1.101.38

Profitability

ROE (TTM)

Both companies show strong equity returns, but Halozyme Therapeutics (HALO) at 216.38% is the standout with ROE above its industry range; Bio-Rad Laboratories (BIO.B) at 14.27% also sits in the top quartile.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
109.18%
BIO.B
14.27%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

216.38%

HALO
216.38%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Bio-Rad Laboratories (BIO.B) at 39.45% and Halozyme Therapeutics (HALO) at 26.93% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO.B
39.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.93%

HALO
26.93%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Halozyme Therapeutics (HALO) at 56.68% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO.B) at 9.46%, which runs around its industry’s norm.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.46%

Max
83.12%
Q3
14.77%
BIO.B
9.46%
Median
0.00%
Q1
-78.82%
Min
-207.40%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

56.68%

Max
83.12%
HALO
56.68%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO)
MetricBIO.BHALO
ROE (TTM)14.27%216.38%
ROA (TTM)1.50%22.42%
Net Margin (TTM)39.45%26.93%
Operating Margin (TTM)9.46%56.68%
Gross Margin (TTM)52.19%76.00%

Growth

Revenue Growth

Both Bio-Rad Laboratories (BIO.B) at 0.65% and Halozyme Therapeutics (HALO) at 37.55% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Halozyme Therapeutics (HALO) reports EPS growth of -25.36%, ranked against its industry; Bio-Rad Laboratories (BIO.B) has no EPS growth figure this period.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO)
MetricBIO.BHALO
Revenue Growth (YoY)0.65%37.55%
Revenue Growth (3Y CAGR)-2.68%28.38%
EPS Growth (YoY)---25.36%
EPS Growth (3Y CAGR)--21.14%

Financial Strength

Current Ratio (MRQ)

Both Bio-Rad Laboratories (BIO.B) at 3.18 and Halozyme Therapeutics (HALO) at 3.88 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max
25.13
Q3
12.13
Median
5.52
BIO.B
3.18
Q1
2.47
Min
0.10

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.88

Max
25.13
Q3
12.13
Median
5.52
HALO
3.88
Q1
2.47
Min
0.10
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Bio-Rad Laboratories (BIO.B) carries debt-to-equity ratio of 0.18 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max
1.42
Q3
0.65
BIO.B
0.18
Median
0.15
Q1
0.02
Min
0.00

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
HALO
--
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO): HALO does not report debt-to-equity ratio, so it has no value marker; BIO.B is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO)
MetricBIO.BHALO
Current Ratio (MRQ)3.183.88
Debt / Equity (MRQ)0.18--
Net Debt / EBITDA-0.731.93

Dividends

Dividend Yield (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO)
MetricBIO.BHALO
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO.B) at 10.36 sits in the cheaper P/E ratio quartile, while Halozyme Therapeutics (HALO) at 25.07 is closer to its industry’s usual earnings multiple — a discount for BIO.B, though growth and earnings durability still matter.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.36

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
BIO.B
10.36
Min
0.07

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.07

Max
85.34
Q3
43.46
Median
26.69
HALO
25.07
Q1
13.30
Min
0.07
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Bio-Rad Laboratories (BIO.B) at 4.05 and Halozyme Therapeutics (HALO) at 6.34 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.05

Max
58.18
Q3
25.77
Median
7.30
BIO.B
4.05
Q1
3.01
Min
0.01

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.34

Max
58.18
Q3
25.77
Median
7.30
HALO
6.34
Q1
3.01
Min
0.01
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -206.74, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Bio-Rad Laboratories (BIO.B) reports 1.38, ranking against industry peers normally.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BIO.B
1.38
Min
-5.59

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-206.74

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
HALO
-206.74
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Halozyme Therapeutics (HALO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bio-Rad Laboratories (BIO.B) and Halozyme Therapeutics (HALO)
MetricBIO.BHALO
P/E Ratio (TTM)10.3625.07
P/S Ratio (TTM)4.056.34
P/B Ratio (MRQ)1.38-206.74
Free Cash Flow Yield (TTM)2.59%3.74%